LANGERHANS CELL HISTIOCYTOSIS: Retrospective Evaluation of 123 Patients at a Single Institution
- 1 January 1999
- journal article
- research article
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 16 (5) , 377-385
- https://doi.org/10.1080/088800199276921
Abstract
The aim of this study was to retrospectively evaluate clinical characteristics at diagnosis and outcome of patients with Langerhans cell histiocytosis (LCH). From October 1987 to March 1996, 133 patients with confirmed LCH were admitted to Hospital JP Garrahan in Buenos Aires (123 evaluable). Median age was 5 years (range 15 days to 18 years). Initial organ involvement included bone 114 patients, ear 34, skin 30, liver 18, lung 14, lymph nodes 14, spleen 12, diabetes insipidus 9, and bone marrow 2. Nineteen patients had organ dysfunction, pulmonary 14, hematological 14, and hepatic 12. Two groups were defined: Group A included patients with single system disease (unior multifocal) and group B multisystem (with or without organ dysfunction). In group A (n = 82), 24 patients were treated with chemotherapy (prednisone and vinblastine), 21 with surgery, 15 received radiotherapy, and 22 were only observed. Patients of group B ( n = 41) were treated with chemotherapy consisting of prednisone and vinblastine, DALHX 83, or LCH1-based chemotherapy. At a median follow-up of 3 years (range 1 month-8 5/12 years) 93% of patients of group A and 39% of group B survive free of reactivation. In group B, 22% had a reactivation and 39% died of progressive disease. Sequelae were detected in 35 patients (28%), which included diabetes insipidus in 17, hearing loss in 13, bony sequelae in 11, sclerosing cholangitis in 6, and lung fibrosis with bullae in 6. Two patients had a subsequent malignant disease. A total of 17 (14%) patients died and 16 of them belonged to the group B: 13 died of progressive disease, 2 due to sclerosing cholangitis (with sepsis in one case and encephalitis in the other one), 1 with progressive disease and associated myelofibrosis, and 1 patient of group A with active disease and brain stem tumor. Patients who had organ dysfunction had a reactivation free survival of 32%. All these patients survived with sequelae. Logistic regression analysis showed that organ dysfunction and hematological involvement had significant predictive values in relation to death. Patients of group A had an excellent survival rate, whereas in those of group B a high mortality was found, especially in the subgroup of patients with organ dysfunction. Lahey's criteria should be revised. Sequelae were also more common in this group.Keywords
This publication has 10 references indexed in Scilit:
- Diabetes insipidus associated with Langerhans cell histiocytosis: Is it reversible?Medical and Pediatric Oncology, 1997
- A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group.Archives of Disease in Childhood, 1996
- Langerhans cell histiocytosis in children under 2 years of ageMedical and Pediatric Oncology, 1996
- Diabetes insipidus in langerhans cell histiocytosi: Results from the DAL‐HX 83 studyMedical and Pediatric Oncology, 1995
- LCH‐I: A randomized trial of etoposide vs. vinblastine in disseminated langerhans cell histiocytosisMedical and Pediatric Oncology, 1994
- Association of malignancy and langerhans' cell histiocytosis: Report of three casesMedical and Pediatric Oncology, 1993
- Langerhans cell histiocytosis in childhood: Results from the Italian cooperative AIEOP‐CNR‐H.X '83 studyMedical and Pediatric Oncology, 1993
- Langerhans' cell histiocytosis (Histiocytosis X): Experience at the children's hospital of philadelphia, 1970–1984Medical and Pediatric Oncology, 1989
- Natural history of histiocytosis X: A pediatric oncology group studyMedical and Pediatric Oncology, 1986
- Histiocytosis X—an analysis of prognostic factorsThe Journal of Pediatrics, 1975